Literature DB >> 33510581

Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis.

Ivan Wudexi1, Elica Shokri1, Mohamed Abo-Aly1, Kazuhiro Shindo1, Ahmed Abdel-Latif1.   

Abstract

METHODS: We conducted a network meta-analysis of randomized controlled trials that studied the effects of anti-inflammatory medications on cardiovascular outcomes of coronary artery disease patients. We searched the electronic database until March 2020 for relevant studies.
RESULTS: Nineteen trials examining the efficacy of eight anti-inflammatory medications (pexelizumab, anakinra, colchicine, darapladib, varespladib, canakinumab, inclacumab, and losmapimod) were selected for analysis. Overall, there is no statistically significant difference in all-cause mortality, cardiovascular mortality, revascularization, and major cardio and cerebrovascular events (MACCE) with the use of anti-inflammatory drugs. However, we found the use of colchicine significantly reduces the odds of developing stroke by approximately 75% (OR 0.26, CI 0.10-0.63). Colchicine use was also associated with a lower risk of revascularization and MACCE compared to the other agents. Our subgroup analyses comparing the timing of medication initiation (within 7 days vs. >7 days) and clinical presentation (ACS vs. non-ACS) revealed a significant reduction in the risk of recurrent MI in the group that received medication after seven days (OR 0.92, CI 0.86-0.99) and the non-ACS group (OR 0.88, CI 0.80-0.98).
CONCLUSION: Although many anti-inflammatory medications have failed to reduce adverse cardiovascular outcomes in the CAD population, selected medications show promise among subgroups of patients without ACS or after the first week following an acute ischemic event. Future studies examining the proper timing and targetable anti-inflammatory pathways are warranted.
Copyright © 2021 Ivan Wudexi et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33510581      PMCID: PMC7822705          DOI: 10.1155/2021/5160728

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  48 in total

1.  Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

Authors:  Robert S Rosenson; Colin Hislop; Michael Elliott; Yuri Stasiv; Michael Goulder; David Waters
Journal:  J Am Coll Cardiol       Date:  2010-09-28       Impact factor: 24.094

2.  Darapladib for preventing ischemic events in stable coronary heart disease.

Authors:  Harvey D White; Claes Held; Ralph Stewart; Elizabeth Tarka; Rebekkah Brown; Richard Y Davies; Andrzej Budaj; Robert A Harrington; P Gabriel Steg; Diego Ardissino; Paul W Armstrong; Alvaro Avezum; Philip E Aylward; Alfonso Bryce; Hong Chen; Ming-Fong Chen; Ramon Corbalan; Anthony J Dalby; Nicolas Danchin; Robbert J De Winter; Stefan Denchev; Rafael Diaz; Moses Elisaf; Marcus D Flather; Assen R Goudev; Christopher B Granger; Liliana Grinfeld; Judith S Hochman; Steen Husted; Hyo-Soo Kim; Wolfgang Koenig; Ales Linhart; Eva Lonn; José López-Sendón; Athanasios J Manolis; Emile R Mohler; José C Nicolau; Prem Pais; Alexander Parkhomenko; Terje R Pedersen; Daniel Pella; Marco A Ramos-Corrales; Mikhail Ruda; Mátyás Sereg; Saulat Siddique; Peter Sinnaeve; Peter Smith; Piyamitr Sritara; Henk P Swart; Rody G Sy; Tamio Teramoto; Hung-Fat Tse; David Watson; W Douglas Weaver; Robert Weiss; Margus Viigimaa; Dragos Vinereanu; Junren Zhu; Christopher P Cannon; Lars Wallentin
Journal:  N Engl J Med       Date:  2014-03-30       Impact factor: 91.245

3.  Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling.

Authors:  Yuichiro Maekawa; Toshihisa Anzai; Tsutomu Yoshikawa; Yasushi Asakura; Toshiyuki Takahashi; Shiro Ishikawa; Hideo Mitamura; Satoshi Ogawa
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

4.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

Authors:  Jean-Claude Tardif; Simon Kouz; David D Waters; Olivier F Bertrand; Rafael Diaz; Aldo P Maggioni; Fausto J Pinto; Reda Ibrahim; Habib Gamra; Ghassan S Kiwan; Colin Berry; José López-Sendón; Petr Ostadal; Wolfgang Koenig; Denis Angoulvant; Jean C Grégoire; Marc-André Lavoie; Marie-Pierre Dubé; David Rhainds; Mylène Provencher; Lucie Blondeau; Andreas Orfanos; Philippe L L'Allier; Marie-Claude Guertin; François Roubille
Journal:  N Engl J Med       Date:  2019-11-16       Impact factor: 91.245

5.  Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.

Authors:  Kenneth W Mahaffey; Christopher B Granger; Jose C Nicolau; Witold Ruzyllo; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Christopher F Mojcik; Thomas G Todaro; Paul W Armstrong
Journal:  Circulation       Date:  2003-08-18       Impact factor: 29.690

6.  Low-dose colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Charley A Budgeon; Peter L Thompson
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

7.  Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study.

Authors:  Kaivan Vaidya; Clare Arnott; Gonzalo J Martínez; Bernard Ng; Samuel McCormack; David R Sullivan; David S Celermajer; Sanjay Patel
Journal:  JACC Cardiovasc Imaging       Date:  2017-10-18

Review 8.  The inflammatory response in myocardial injury, repair, and remodelling.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2014-03-25       Impact factor: 32.419

Review 9.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

Authors:  Deborah M Caldwell; A E Ades; J P T Higgins
Journal:  BMJ       Date:  2005-10-15

10.  Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.

Authors:  Antonio Abbate; Cory R Trankle; Leo F Buckley; Michael J Lipinski; Darryn Appleton; Dinesh Kadariya; Justin M Canada; Salvatore Carbone; Charlotte S Roberts; Nayef Abouzaki; Ryan Melchior; Sanah Christopher; Jeremy Turlington; George Mueller; James Garnett; Christopher Thomas; Roshanak Markley; George F Wohlford; Laura Puckett; Horacio Medina de Chazal; Juan G Chiabrando; Edoardo Bressi; Marco Giuseppe Del Buono; Aaron Schatz; Chau Vo; Dave L Dixon; Giuseppe G Biondi-Zoccai; Michael C Kontos; Benjamin W Van Tassell
Journal:  J Am Heart Assoc       Date:  2020-03-03       Impact factor: 6.106

View more
  2 in total

1.  Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome.

Authors:  Cheng Wang; Yan Wu; Yang Su; Bin Mao; Yihong Luo; Yexiang Yan; Kun Hu; Yi Lu; Wenliang Che; Minying Wan
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-19       Impact factor: 2.357

2.  A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.

Authors:  José Luis Marín-Rubio; Rachel E Peltier-Heap; Maria Emilia Dueñas; Tiaan Heunis; Abeer Dannoura; Joseph Inns; Jonathan Scott; A John Simpson; Helen J Blair; Olaf Heidenreich; James M Allan; Jessica E Watt; Mathew P Martin; Barbara Saxty; Matthias Trost
Journal:  J Med Chem       Date:  2022-09-12       Impact factor: 8.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.